America’s offshore comeback begins: BBG1 lease sale attracts $279m in high bids as energy dominance strategy accelerates
The U.S. raised $279M in its first offshore lease sale under the One Big Beautiful Bill Act. Find out which companies dominated the Gulf of America auction.
Why is the UK spending £7bn on new prisons—and will it work?
Discover how the UK’s historic prison building programme is changing justice and safety. Read more for insights on jobs, reform, and public impact.
Bell Financial Group (ASX: BFG) shares jump 8% as profit before tax rises 17% YTD
Bell Financial Group profit before tax rises 17% year-to-date in 2025, powered by tech platforms and broking gains. Find out what’s behind the turnaround.
Leqembi gains traction in China as commercial insurance innovative drug list expands access for Alzheimer’s patients
Leqembi gains commercial insurance status in China, opening doors for Alzheimer’s patients and transforming access. Find out what this means for BioArctic AB and Eisai.
Innovent Biologics achieves key milestone as PECONDLE delivers sustained efficacy in Phase 3 psoriasis trial
Find out how Innovent’s PECONDLE is redefining long-term psoriasis care with sustained response and quarterly dosing.
Myelofibrosis breakthrough? Incyte’s INCA033989 delivers clinical and molecular wins
Incyte’s mutCALR antibody shows promise in myelofibrosis and ET. Find out what ASH 2025 data reveals about INCA033989’s future potential.
Gilead’s CAR T breakthrough: Yescarta delivers consistent results beyond transplant settings
Yescarta shows durable survival and response benefits in second-line large B-cell lymphoma across transplant-eligible and ineligible patients. Read the latest trial update.
Can Epcoritamab plus R2 become the new second-line standard in follicular lymphoma after Genmab’s Phase 3 success?
Genmab’s Epcoritamab plus R2 combo cut FL relapse risk by 79% in Phase 3. Find out why this bispecific therapy may reshape second-line treatment.
Can HYMPAVZI change hemophilia care for patients with inhibitors? Pfizer’s Phase 3 results signal a new standard
Pfizer’s HYMPAVZI showed 93% fewer bleeds in hemophilia patients with inhibitors. Explore how this subcutaneous treatment could redefine care standards.
Can VGA039 become a once-monthly standard of care for von Willebrand disease?
Star Therapeutics' VGA039 shows strong bleeding reduction across all VWD types in Phase 1/2 trial. Discover how this monthly shot could change the standard of care.